Asthma affects approximately 240 million people worldwide. It is characterised by an allergic pattern of smooth muscle constriction and airway inflammation, and if chronic, the inflammation can lead to structural changes and fixed airflow obstruction. Bronchodilators relieve the bronchoconstriction, while inhaled corticosteroids reduce the airway inflammation. This paper reviews fluticasone furoate (FF), a novel inhaled corticosteroid with 24-hour duration of action. It is a synthetic fluorinated corticosteroid with agonist activity at the glucocorticoid receptor (GRE). It is reported to have a fast association and slow dissociation from the GRE compared to other ICSs. FF has been found to have a greater lung retention time than all other ICS preparations which may contribute to the extended duration of anti-inflammatory action. FF has extensive first pass hepatic metabolism resulting in a low gastrointestinal bioavailability which is consistent with the findings for other ICS preparations. FF, however, will pass from the lung into the systemic circulation and therefore an adverse profile similar to all ICS is likely, but long term data are needed.
Introduction
Asthma is estimated to affect over 240 million people worldwide 1 . It is a heterogeneous disease, defined by symptoms which include wheeze, shortness of breath, chest tightness and cough. Asthma varies in intensity and over time, being characterised by variable expiratory airflow obstruction and inflammation.
Th2 asthma is caused characteristically by an allergic pattern of inflammation in the airways, involving initial sensitization to allergens, infiltration by antigen presenting cells such as dendritic cells, inflammatory cells (eosinophils and T-helper 2 (Th2) cells) and IgE priming of mast cells 2, 3, 4 . Less commonly, an alternate pathway has been described that can contribute to the development of low-Th2 asthma. These factors include infection-related elements, Th1 and Th17 immunity; non-Th2 associated smooth-muscle changes and the development of neutrophilic inflammation include hypertrophy and hyperplasia of airway smooth muscle cells, fibrosis, angiogenesis, and hyperplasia of mucus-secreting cells 3, 5 . Chronic inflammation can lead to structural changes and fixed airflow obstruction.
Oral corticosteroid therapy has proved efficacious for the treatment of asthma for many decades. To mitigate against some of the systemic side effects, inhalational therapy was a logical, effective solution. This coupled with the fact that asthma pathology is largely confined to the airways of the lungs has made inhaled corticosteroid (ICS) therapy the gold standard method for anti-inflammatory drug delivery 6, 7 .
Glucocorticoids are the most effective anti-inflammatory treatment in asthma and switch off multiple activated pro-inflammatory genes 8 . Treatment with inhaled corticosteroids has been demonstrated, through histological specimens, to produce a reduction in mast cells, eosinophils, T lymphocytes and dendritic cells in the mucosa and submucosa; reduced goblet hyperplasia and epithelial-cell injury and decreased vascularity. However, neutrophilic inflammation is less likely to respond to ICS. No other drug class to date has demonstrated a greater effect in preventing adverse asthma-related outcomes than ICS
.
In those with poorly controlled asthma, it is estimated that this is due to poor adherence with preventative therapy in more than half of the patients, at least to some degree 10 . Over-confidence and misuse of inhaled β 2 -adrenergic therapy have also been shown to increase the risk of hospitalisation in asthmatics 11, 12 .
Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24-hour duration of action with proven efficacy morning and evening 13 . This paper reviews the literature supporting the use of FF as a once daily maintenance treatment of asthma in adults and adolescents over the age of 12. A once daily inhaled corticosteroid could potentially improve compliance with medication and therefore reduce the risk of poor asthma-related outcomes associated with poor adherence 1, 14 .
Structure
The chemical composition of FF is C 27 H 29 F 3 O 6 S and is demonstrated below (Figure 1 ). It can be administered as a single agent via the inhalational route or in combination with a long acting β 2 -agonist (LABA) 15 . It is a synthetic fluorinated corticosteroid with agonist activity at the glucocorticoid receptor (GRE).
Fluticasone propionate (FP) is a well-established ICS for the treatment of asthma 9 . Although FF and FP are structurally related, they are chemically and pharmacologically distinct. They share no common metabolites nor are they metabolised to fluticasone, acting not as pro-drugs but as distinct drug molecules 16 . Differences between FF and FP were shown using x-ray crystallography demonstrating the ester derived from FF occupying a discreet pocket on the glucocorticoid receptor more fully than FP
17
. This suggests higher affinity of FF for both lung and nasal tissue 18 .
Efficacy

Pre-clinical Studies
The pharmacological properties of FF were examined in vitro and in vivo models of respiratory inflammatory disease (i.e. asthma and chronic obstructive pulmonary disease (COPD)). The potency of FF activity on the glucocorticoid response element (GRE) was examined 20 .
In an assay of lipopolysaccharide-stimulated tumour necrosis factor (TNF-alpha) release from peripheral blood mononuclear cells and transrepression nuclear factor-ĸB (NF-ĸB) reporter assays using a human lung epithelial cell line the anti-inflammatory effects of FF have been studied. Again, FF was compared with FP, MF, BUD and CIC. FF showed the highest potency of all the corticosteroids tested, with MF demonstrating a similarly high potency in the NF-ĸB assay. This study also demonstrated that FF had the largest cellular accumulation and the slowest rate of efflux relative to other clinically used glucocorticoids 18 . Additionally, in vitro, the rate of transport of FF out of the cells in the basal aqueous layer was slower than the other glucocorticoids, again consistent with retention of FF in respiratory tissues, which has been described. This is thought likely to contribute to an extended duration of anti-inflammatory action 19 .
Clinical Research studies
A Phase 0 study looking at metabolism and disposition of FF in 5 healthy male adults indicated systemic exposure from oral preparations had extensive first pass hepatic metabolism resulting in very low gastrointestinal bioavailability (recorded as 1.6%) which is consistent with the findings for other ICS preparations 21 . Systemic availability of budesonide after oral administration was found to be approximately 10%
22
. Interestingly, a study assessing the effect of systemic absorption of FP on adrenal glucocorticoid secretion via urinary cortisol in 28 asthmatic patients demonstrated that FP is likely to induce a decrease in nocturnal cortisol secretion in those with less severe airway obstruction, demonstrating variability of systemic bioavailability and possibly the effect being secondary to the amount of peripheral drug lung deposition in the target population 23 . No data have been published for FF in this regard.
The major route for metabolism of fluticasone furoate in humans is mediated primarily by Cytochrome P450 3A4 (CYP3A4). FF is converted by hydrolysis of the S-fluoromethyl carbthioate group to metabolites with significantly reduced corticosteroid activity. FF is also known to be a substrate of P-glycoprotein 24 . A repeat dose CYP3A4 drug interaction study was performed in healthy subjects with FF/VIL (200μg/25μg) and a strong inhibitor of CYP3A4, ketoconazole 400μg. The administration of both of these agents lead to an increase in the area under the curve( 0-24 ) and maximal plasma concentration (Cmax) by 36% and 33% respectively. This subsequently led to a 27% reduction in serum cortisol, which could potentially lead to an increase in adverse events 24 . A Phase I study of FF and FP in 24 healthy male subjects showed the half-life (t1/2) for inhaled FF was longer than the estimated halflife for intravenous (IV) FF (17-24 h vs 14 h, respectively), in contrast, the half-life for FP was similar whether inhaled or given intravenously (11 and 14 h, respectively). This would suggest that FF is exhibiting absorption rate-limited pharmacokinetics following inhalation. The time for 90% absorption from the lung was also measured and found to be significantly longer for FF (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) 
28
. However, dose adjustments were deemed unnecessary because there had been no associated clinically significant effect on serum cortisol.
A study published in 2016 has also shown FF as an effective step-down agent from combination ICS/LABA to a single ICS monotherapy. A multicentre randomised control trial (RCT) assessed 430 Japanese asthma patients. This involved run in with ICS/LABA (FF/Vilanterol -VIL) in well-controlled asthmatics. This study demonstrated that step down to FF 100μg maintained similar control as compared with FP 100μg BD and FP 250μg BD with asthma control maintained at 89.5%, compared with 78.2% and 83.1% respectively
29
. The study was not powered to detect treatment differences nor did the study mention if these differences were statistically significant. . budesonide, by comparison, has shown a dose-dependent response when using commercially available inhalers 36, 37 . Single maintenance and reliever therapy (or 'SMART)' has been described with this ICS preparation in combination with the LABA, formoterol 38 .
FF has demonstrated clinical efficacy at both 100μg and 200μg, which are now the commercially licensed inhaled doses 39 . Patients were randomised to either 100μg or 200μg FF and improvements in lung function were seen in both groups. Greater improvements in FEV 1 with the higher dose were noted at week 24, the end of the study period, however, this failed to reach significance (77ml 95% CI Despite MF having reportedly less specificity for the glucocorticoid receptor 45 , this ICS preparation has proved efficacious with once daily dosing also 46 . No head to head comparisons of this or other ICS preparations with oncedaily FF have been undertaken.
Adverse event profile
FF has a low oral bioavailability due to limited absorption and extensive first pass metabolism, therefore any drug swallowed is thought unlikely to produce significant systemic side effects in most circumstances 47 . However, inhaled FF will pass from the lung into the systemic circulation and therefore an adverse profile similar to all ICS needs to be considered.
ICS related side effects are mainly due to either local deposition in the oropharynx or systemic absorption via the lung and the effect they have on the hypothalamicpituitary-axis (HPA). Studies to demonstrate the effect on the HPA largely involve screening tests demonstrating a reduction the 24-hour urinary cortisol (UC) or performing a 24-hour integrated measurement of plasma cortisol levels which are impractical and challenging to achieve in an outpatient setting 48 .
Due to these issues, the side effect profile of FF is routinely studied using the rates of oropharyngeal candidiasis and, as mentioned, a reduction in total 24-hour UC levels.
Oropharyngeal candidiasis demonstrates a dose dependent relationship with FF, occurring in 1% to 4% of patients taking doses up to 400µg 35, 43, 49, 50 which increases to 12% when inhaling 800µg FF per day 35 .
Urinary cortisol suppression has been reported for FF in a variable manner. No clinically significant difference in 24hr UC compared with placebo using doses up to 400µg OD has been seen 35, 43, 49, 50 . However, doses at 800µg of FF vs placebo indicated UC suppression Other potential long term adverse drug reactions and complications include osteoporosis, increased risk of mycobacterial infections, cataracts, hypertension, and diabetes mellitus are likely to occur. Currently, no direct data exist to further quantify the risk of these expected side effects with this drug versus the risks with other inhaled corticosteroids. FF is likely to be a more potent ICS
19
, and therefore extra care may need to be taken with the drug to avoid systemic side effects.
The well documented risk of ICS causing an increase in pneumonia in COPD patients by the TORCH 52 and FLAME 53 studies provoked interest into whether this effect was translated in the asthmatic population. A Canadian study which identified 1928 pneumonia cases in over 150, 000 patients using ICS suggesting an increased risk of pneumonia associated with current use of ICS [RR 1.83; 95% confidence interval (CI) 1.57, 2.14]
54
. To date there do not appear to be data to suggest that this signal has been investigated for FF. Further work is needed to assess risk in asthmatics, especially as the recent IMPACT
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, Salford Lung Study 56 and Summit 57 studies all showed that COPD patients using an ICS, in these instances FF, was again associated with an increased pneumonia risk.
Drug Delivery
FF is inhaled using the ELLIPTA® dry powder inhaler (DPI) device
39
. The ELLIPTA® multi-dose inhaler has been developed for the delivery of inhaled medication in patients with airways disease with demonstrated efficacy at different flow rates -30, 60 and 90L/min 58 . In addition, this device has been shown to be less prone to inhaler errors in patients with COPD
59
. Both asthma and COPD patients also showed a preference to the ELLIPTA® DPI device when compared with the other inhalation devices tested 59 .
Discussion
Fluticasone furoate is a novel inhaled corticosteroid with a long lung retention time and fast association and slow dissociation from the glucocorticoid receptor compared to other ICS
19
. Thomas and colleagues demonstrated that either evening or morning doses of FF at a dose of 100 μg produced similar improvements in lung function compared with placebo
13
. The pharmacological profile of FF has been demonstrated in multiple preclinical and clinical studies with 24-hour duration of action, making it an acceptable option for once daily dosing.
FF has demonstrated non-inferiority to FP and is therefore an alternative to this ICS twice daily medication. Budesonide and mometasone may be more desirable ICS preparations given the fact that FF, like FP, has not been demonstrated to have a dose-response effect. Nevertheless, FF at low dose has demonstrable efficacy and could be used for many patients with persistent asthma uncontrolled by short acting β2-agonists alone, and the lowest effective dose should be used in accordance with the GINA guidelines Currently, its side effect profile does not present additional concern that would lead physicians to consider the medication more hazardous than other ICS preparations but with a long retention time, other side effects may be recognised later. Adverse effects including oropharyngeal candidiasis and adrenal suppression are likely to be associated with higher doses of FF. The FF adverse profile appears similar to other ICS preparations. There is an increased risk of pneumonia identified in patients with airways disease with the use of some ICS preparations and as it is likely to be a class effect, this will need to be observed in large scale studies to identify whether FF also demonstrates this signal.
It is recognised that personality traits and beliefs about medicine will directly affect adherence to asthma treatment, however, ease of administration also plays a significant role 61 . Once daily therapy, such as FF could hopefully be translated into further improvements in asthma-related outcomes in the future, however, to date the evidence for this over twice daily dosing is currently lacking.
